Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-254-5 | CAS number: 118-47-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Data is from peer reviewed publication
Data source
Reference
- Reference Type:
- publication
- Title:
- A 90 day Oral Toxicity Study Of Tartrazine, A Synthetic Food Dye, In Wistar Rats
- Author:
- Imane Himri, Said Bellahcen, Faiza Souna, Fatima Belmekki, Mohammed Aziz, Mohamed Bnouham, Jouhar Zoheir, Zolikha Berkia, Hassane Mekhfi, Ennouamane Saalaoui
- Year:
- 2 011
- Bibliographic source:
- International Journal of Pharmacy and Pharmaceutical Sciences, Vol 3, Suppl 3, 2011
Materials and methods
- Principles of method if other than guideline:
- 13 week subchronic toxicity study was conducted to evaluate the repeated dose toxic nature of the test compound tartrazine.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Trisodium 5-hydroxy-1-(4-sulphophenyl)-4-(4-sulphophenylazo)pyrazole-3-carboxylate
- EC Number:
- 217-699-5
- EC Name:
- Trisodium 5-hydroxy-1-(4-sulphophenyl)-4-(4-sulphophenylazo)pyrazole-3-carboxylate
- Cas Number:
- 1934-21-0
- IUPAC Name:
- trisodium 5-hydroxy-1-(4-sulphophenyl)-4-(4-sulphophenylazo)pyrazole-3-carboxylate
- Reference substance name:
- trisodium 5-hydroxy-1-(4-sulphophenyl)-4-(4-sulphophenylazo) pyrazole-3-carboxylate
- IUPAC Name:
- trisodium 5-hydroxy-1-(4-sulphophenyl)-4-(4-sulphophenylazo) pyrazole-3-carboxylate
- Details on test material:
- - Name of test material (as cited in study report): Tartrazine
- Molecular formula (if other than submission substance): C16-H12-N4-O9-S2.3Na.
C16-H9-N4-O9-S2.3Na
- Molecular weight (if other than submission substance): 534.3681 g/mol
- Substance type: Organic
- Physical state: No data available
- Impurities (identity and concentrations): 86.7% pure
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Source: No data available
- Age at study initiation: No data available
- Weight at study initiation: 170-200 g
- Fasting period before study: No data available
- Housing: housed in transparent
polypropylene cages in a controlled room
- Diet (e.g. ad libitum): dry rat pellets feeds (Societé Sonabetail, Oujda, Morocco) ad libitum
- Water (e.g. ad libitum): Water ad libitum
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): No data available
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): 12 h light‐dark cycle
IN-LIFE DATES: From: To: No data available
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: Distilled water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Tartrazine was dissolved in distilled water.
DIET PREPARATION
- Rate of preparation of diet (frequency): No data available
- Mixing appropriate amounts with (Type of food): No data available
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): distilled water
- Concentration in vehicle: 0, 5, 7.5, or 10 mg/kg b.w.
- Amount of vehicle (if gavage): 10mL/Kg
- Lot/batch no. (if required): No data available
- Purity: No data available - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data available
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 5, 7.5, or 10 mg/kg b.w.
Basis:
- No. of animals per sex per dose:
- Total: 24
0 mg/Kg bw: 3/sex/dose
5 mg/Kg bw: 3/sex/dose
7.5 mg/Kg bw: 3/sex/dose
10 mg/Kg bw: 3/sex/dose - Control animals:
- yes, concurrent vehicle
- Details on study design:
- No data available
- Positive control:
- No data available
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
- Cage side observations checked in table [No.?] were included. General conditions
DETAILED CLINICAL OBSERVATIONS: Yes / No / No data
- Time schedule:
BODY WEIGHT: Yes
- Time schedule for examinations: Once every 10 days, on the first and the last days of the period, and on the day of necropsy
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, once a week
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
- Time schedule for examinations:
OPHTHALMOSCOPIC EXAMINATION: No data
- Time schedule for examinations: No data
- Dose groups that were examined: No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the end of 13 weeks
- Anaesthetic used for blood collection: No data
- Animals fasted: Yes, all rats were deprived of food, but not water, overnight
- How many animals: All animals
- Parameters checked in table [No.?] were examined. Hematological evaluations included red blood cell count (RBC), hemoglobin concentration (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular haemoglobin
(MCH), mean corpuscular hemoglobin concentration (MCHC), red cell volume distribution (RDW), blood platelet count (PLT), mean platelet volume (MPV), and white blood cell count (WBC), differential leukocyte percentage and reticulocyte ratio were measured.
For morphological examination differential counts of leukocytes
were made by light microscopical observation of smear specimens stained with a routine May– Glünwald–Giemsa protocol.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the end of 13 weeks
- Animals fasted: Yes, all rats were deprived of food, but not water, overnight
- How many animals: All animals
- Parameters checked in table [No.?] were examined. Parameters included Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), blood urea nitrogen (BUN), CREatinine (CRE), GLUcose (GLU), Total CHOlesterol (T‐CHO), Triglyceride (TG), Total Protein (TP).
URINALYSIS: No
- Time schedule for collection of urine: No
- Metabolism cages used for collection of urine: No
- Animals fasted: No
- Parameters checked in table [No.?] were examined.
NEUROBEHAVIOURAL EXAMINATION: No
- Time schedule for examinations: No
- Dose groups that were examined: No
- Battery of functions tested: No sensory activity / grip strength / motor activity / other: No
OTHER: Organ weights were obtained for the heart, lung, liver, spleen, and stomach. Relative organ weights were calculated based on body weights measured on the day of sacrifice. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, Animals were then killed by exsanguination from the abdominal aorta. The body surface, the intrathracic, intra‐abdominal organs and tissues were observed macroscopically.
HISTOPATHOLOGY: A portion of each organ was fixed in 10% neutral buffered formalin for histopathology, and was further processed using standard method. The micro‐sections of 5 μm thicknesses were stained with hematoxylin–eosin and the prepared slides were examined under light microscope for histopathological. - Other examinations:
- No data available
- Statistics:
- The statistical significance of the differences between control and experimental groups was evaluated by Student’s t‐test using GraphPad Instat 3.06
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- Clinical signs and mortality: During the administration period, no deaths occurred in animals of any group. There were no abnormal signs in all groups.
Body weight and weight gain: Compared to the water control group, treatment with Tartrazine did not affect body weights.\
Food consumption and compound intake: Compared to the water control group, treatment with Tartrazine did not affect food intake.
Food efficiency: No data available
Water consumption and compound intake: No data available
Opthalmoscopic examination: No data available
Haematology: Hematology results did not reveal significant changes in group control and group treated with 10 mg/kg b.w of Tartrazine. But a significantly higher mean platelet volume, neutrophile and basophile; and a significantly lower blood platelet count in group treated with 7.5 mg/kg b.w of Tartrazine was noted.
Clinical chemistry: The levels of GLU, CREA, were significantly increased in all groups compared to group control. The levels of CHOL, TG were significantly increased in group treated with 7.5, 10 mg/kg b.w of Tartrazine. There was no significant difference in the level of BUN and ALT among the different groups. The level of AST was significantly in group treated with 10 mg/kg b.w of Tartrazine. The total Protein was significantly increased in group treated with 7.5, 10 mg/kg b.w of Tartrazine.
Urinanalysis: No data available
Neurobehaviour: No data available
Organ weights: The differences in mean organ weights between control and treated groups (5, 7.5, 10 (mg/kg b.w) of Tartrazine were nonsignificant.
Gross pathology: No data available
Histopathology: All the tissue sections obtained from the stomach of experimental Wistar rats fed with 5, 7.5, 10 mg/ (kg BW) of Tartrazine. All the sections were essentially normal without any inflammatory lesion.
The histopathological examination showed lymphoid infiltrates in the Jejunum of rats fed with 7.5, 10 mg/ (kg BW) of Tartrazine.
The histopathological studies showed brown pigment deposition in the Küpffer cells and fatty degeneration of the liver in groups treated with 7.5, 10 mg/ (kg BW) of Tartrazine.
Tubular dilatation with thickened basement membrane in group treated with 5 mg/ (kg BW) of Tartrazine, tubular degeneration, and dilatation of the glomerular capillaries in group treated with 7.5 mg/ (kg BW) of Tartrazine, and intercapillary sclerosis, atrophy of glomerulus in group treated with 10 mg/ (kg BW) of Tartrazine was noted.
Effect levels
- Dose descriptor:
- LOAEL
- Effect level:
- 7.5 mg/kg bw (total dose)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: neoplastic
- histopathology: non-neoplastic
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The Low Observed adverse effect level (LOAEL) for the test compound tartrazine is found to 7.5 mg/Kg bw.
- Executive summary:
13 week subchronic toxicity study was conducted to evaluate the repeated dose toxic nature of the test compound tartrazine on Wistar rats of both sexes. The animals were divided into 5 groups of 6 animals each, 3 of each sex, and fed a diet containing 5, 7.5, or 10 mg/kg b.w of Tartrazine.
There were no treatment‐related adverse effects with regard to body weight, food and water consumption. Their blood samples were analyzed for
hematological measurements, Glucose, Creatinine, Blood urea nitrogen, Cholesterol total, Triglecerid, alanine amino-transferase, aspartate
amino-transferase.
Tartrazine induced a morphological change from the discoid shape to an echinocytic form in rat RBCs. Relative weights of the liver were significantly increased in group treated with 10 mg/kg b.w, of Tartrazine. An increase in GLU, CREA, CHOL, TG, AST, and total Protein in serum of rats treated with Tartrazine and Sulfanilic acid compared to control rats was observed and these significant changes were more apparent in high doses than low ones. The histopathological changes of Liver and Kidney were in accordance with the biochemical findings.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.